Patents Assigned to ONCOCROSS CO. LTD.
  • Publication number: 20220273642
    Abstract: The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 1, 2022
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang Kim, Sang Yun Park, Ga Eul Yang, Seung Jun Lee
  • Patent number: 11364237
    Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 21, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang Kim
  • Patent number: 11364244
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: June 21, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang Kim, Jin-Woo Choi
  • Patent number: 11219613
    Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: January 11, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventor: Jin Woo Choi
  • Publication number: 20200246343
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 6, 2020
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang KIM, Jin-Woo CHOI
  • Publication number: 20190374538
    Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 12, 2019
    Applicant: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang KIM
  • Publication number: 20190192480
    Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: August 24, 2016
    Publication date: June 27, 2019
    Applicant: ONCOCROSS CO. LTD.
    Inventor: Jin Woo Choi